Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
15 studies found for:    gdc-0973 | Open Studies | Exclude Unknown
Show Display Options
Rank Status Study
1 Recruiting Vemurafenib Plus Cobimetinib in Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Vemurafenib plus cobimetinib;   Device: Positron Emission Tomography;   Procedure: Tissue sampling;   Procedure: Blood sampling
2 Recruiting A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, and Erivedge Treatment Targeted Against Certain Mutations in Cancer Patients
Condition: Neoplasms
Interventions: Drug: Cobimetinib [Cotellic];   Drug: Erlotinib [Tarceva];   Drug: Pertuzumab [Perjeta];   Drug: Trastuzumab [Herceptin];   Drug: Vemurafenib [Zelboraf];   Drug: Vismodegib [Erivedge]
3 Recruiting Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: Cobimetinib
4 Recruiting XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
Conditions: Melanoma;   Skin Cancer
Interventions: Drug: XL888;   Drug: Vemurafenib;   Drug: Cobimetinib
5 Recruiting Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma
Condition: Melanoma
Interventions: Drug: Cobimetinib;   Drug: Vemurafenib
6 Recruiting A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
Condition: Malignant Melanoma
Interventions: Drug: Atezolizumab [TECENTRIQ];   Drug: Cobimetinib;   Drug: Vemurafenib
7 Recruiting A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma
Condition: Metastatic Melanoma, BRAF V600 Mutation Positive
Interventions: Drug: Cobimetinib;   Drug: Vemurafenib
8 Recruiting A Study of Cobimetinib in Combination With Paclitaxel as First-line Treatment for Patients With Metastatic Triple-negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: cobimetinib;   Drug: paclitaxel;   Drug: placebo
9 Recruiting Neoadjuvant Vemurafenib + Cobimetinib in Melanoma: NEO-VC
Condition: Malignant Melanoma
Intervention: Drug: Vemurafenib + cobimetinib
10 Recruiting iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors
Condition: Solid or Brain Tumor With Evidence of RAS/RAF/MEK/ERK Activation
Intervention: Drug: Cobimetinib
11 Recruiting A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)
Conditions: MSI Positive Colorectal Cancer;   MSI Negative Colorectal Cancer
Interventions: Drug: Ipilimumab;   Drug: Nivolumab;   Drug: Cobimetinib
12 Recruiting The Drug Rediscovery Protocol (DRUP Trial)
Conditions: Cancer;   Tumors;   Neoplasm;   Neoplasia
Interventions: Drug: Panitumumab;   Drug: Olaparib;   Drug: Dabrafenib;   Drug: Nilotinib;   Drug: Trametinib;   Drug: Erlotinib;   Drug: Trastuzumab and Pertuzumab (combination treatment);   Drug: Vemurafenib and Cobimetinib (combination treatment);   Drug: Vismodegib;   Drug: Regorafenib;   Drug: Nivolumab
13 Recruiting TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Conditions: Lymphoma, Non-Hodgkin;   Multiple Myeloma;   Advanced Solid Tumors
Interventions: Drug: Erlotinib;   Drug: Axitinib;   Drug: Bosutinib;   Drug: Crizotinib;   Drug: Palbociclib;   Drug: Sunitinib;   Drug: Temsirolimus;   Drug: Trastuzumab and Pertuzumab;   Drug: Vemurafenib and Cobimetinib;   Drug: Vismodegib;   Drug: Cetuximab;   Drug: Dasatinib;   Drug: Regorafenib;   Drug: Olaparib;   Drug: Pembrolizumab
14 Recruiting The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma
Condition: Melanoma
Intervention: Drug: Vemurafenib
15 Recruiting A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer
Conditions: Advanced Adenocarcinoma;   Metastatic Adenocarcinoma
Interventions: Drug: Hydroxychloroquine (HCQ);   Drug: Gemcitabine

Indicates status has not been verified in more than two years